Darolutamide and Fluconazole in Dextrose Injection
Determining the interaction of Darolutamide and Fluconazole in Dextrose Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. When darolutamide was coadministered with itraconazole, a dual P-gp and potent CYP450 3A4 inhibitor, mean darolutamide peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 40% and 70%, respectively, compared to administration of darolutamide alone. The interaction has not been studied with less potent inhibitors or lone inhibitors of CYP450 3A4 or P-gp. MANAGEMENT: Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling. References "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. When darolutamide was coadministered with itraconazole, a dual P-gp and potent CYP450 3A4 inhibitor, mean darolutamide peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 40% and 70%, respectively, compared to administration of darolutamide alone. The interaction has not been studied with less potent inhibitors or lone inhibitors of CYP450 3A4 or P-gp.
MANAGEMENT: Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.
- "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
Generic Name: fluconazole
Brand name: Diflucan
Synonyms: Fluconazole
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Darolutamide-Fluconazole Injection
- Darolutamide-Fluconazole Injection Solution
- Darolutamide-Fluconazole Intravenous
- Darolutamide-Fluconazole Oral Suspension
- Darolutamide-Fluconazole Tablets
- Darolutamide-Flucytosine
- Fluconazole in Dextrose Injection-Darpaz
- Fluconazole in Dextrose Injection-Darunavir
- Fluconazole in Dextrose Injection-Darunavir and Cobicistat
- Fluconazole in Dextrose Injection-Darunavir Oral Suspension
- Fluconazole in Dextrose Injection-Darunavir Tablets
- Fluconazole in Dextrose Injection-Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide